Table 1 Clinical parameters of EAE experiments in SJL/J mice and DA rats (*, p < 0
From: Inhibition of SLPI ameliorates disease activity in experimental autoimmune encephalomyelitis
Incidence Mortality | Disease onset [d] ± StdDev | Cumulative score ± StdDev | Mean maximal score ± StdDev | ||
|---|---|---|---|---|---|
SLPI immunization in passive EAE of SJL/J mice | |||||
SLPI-immunized mice | 10/10 | 0/10 | 23.0 ± 4.6 * | 8.9 ± 4.6 * | 2 ± 0.5 |
OVA-immunized mice | 7/7 | 0/7 | 17 ± 2.8 | 21.4 ± 7.5 | 2.6 ± 0.7 |
SLPI immunization in active EAE of DA rats | |||||
SLPI-immunized rats | 7/8 | 1/8 | 20.9 ± 10.8 | 21.2 ± 19.3 | 2.8 ± 2.0 * |
OVA-immunized rats | 8/8 | 3/8 | 13.8 ± 1.8 | 30.7 ± 9.3 | 4.5 ± 0.8 |
SLPI administration in active EAE of SJL/J mice | |||||
SLPI-treated mice | 6/7 | 1/7 | 11.1 ± 2.4 * | 29.7 ± 15.3 | 3.1 ± 1.5 |
saline-treated mice | 5/5 | 0/5 | 15.2 ± 4.4 | 19.8 ± 5.7 | 2.8 ± 0.4 |